162 related articles for article (PubMed ID: 34940837)
21. How to manage polycythemia vera.
Passamonti F
Leukemia; 2012 May; 26(5):870-4. PubMed ID: 22157736
[TBL] [Abstract][Full Text] [Related]
22. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
23. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
Zhan H; Spivak JL
Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
[TBL] [Abstract][Full Text] [Related]
24. Compound in-cis JAK2 mutant polycythemia vera manifesting as first-onset transient ischemic attack with erythrocytosis and an attenuated JAK2 V617F mutant signal on a quantitative DD-PCR assay.
Ng IKS; Lee PL; Ng LJ; Chua RP; Ng YA; Lee CK; Tan JG; Chan THM; Yan B; Prasad V
Int J Lab Hematol; 2023 Apr; 45(2):e28-e31. PubMed ID: 36205319
[No Abstract] [Full Text] [Related]
25. A Clue in JAK2: Masked Polycythemia Vera.
Rosenstein BE; Ives ST; Wiernik A
Am J Med; 2016 Oct; 129(10):1051-3. PubMed ID: 27427321
[No Abstract] [Full Text] [Related]
26. Progression to polythythemia vera from familial thrombocytosis with germline JAK2 R867Q mutation.
Maie K; Yokoyama Y; Yano Y; Kato T; Nannya Y; Ogawa S; Noguchi M; Sakata-Yanagimoto M; Chiba S
Ann Hematol; 2018 Apr; 97(4):737-739. PubMed ID: 29368262
[No Abstract] [Full Text] [Related]
27. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
28. JAK2 exon 12 mutations in polycythemia vera or idiopathic erythrocytosis.
Martínez-Avilés L; Besses C; Alvarez-Larrán A; Cervantes F; Hernández-Boluda JC; Bellosillo B
Haematologica; 2007 Dec; 92(12):1717-8. PubMed ID: 18056003
[TBL] [Abstract][Full Text] [Related]
29. JAK2 V617F mutation is rare in idiopathic erythrocytosis: a difference from polycythemia vera.
Yoshinaga K; Mori N; Wang YH; Tomita K; Shiseki M; Motoji T
Int J Hematol; 2008 Jul; 88(1):82-87. PubMed ID: 18528646
[TBL] [Abstract][Full Text] [Related]
30. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management.
Tefferi A; Barbui T
Am J Hematol; 2020 Dec; 95(12):1599-1613. PubMed ID: 32974939
[TBL] [Abstract][Full Text] [Related]
31. Erythrocytosis due to presumed polycythemia vera.
Patell R; Theil K; Lichtin A
Cleve Clin J Med; 2016 Sep; 83(9):648-53. PubMed ID: 27618352
[No Abstract] [Full Text] [Related]
32. Tissue factor activity is increased in neutrophils from JAK2 V617F-mutated essential thrombocythemia and polycythemia vera patients.
Reeves BN; Kim SJ; Song J; Wilson KJ; Henderson MW; Key NS; Pawlinski R; Prchal JT
Am J Hematol; 2022 Feb; 97(2):E37-E40. PubMed ID: 34748652
[No Abstract] [Full Text] [Related]
33. Polycythemia vera and the Jak2(V617F) mutation in a case of hereditary spherocytosis.
Fleischman RA
Am J Med Sci; 2013 Oct; 346(4):328-30. PubMed ID: 23588264
[TBL] [Abstract][Full Text] [Related]
34. [Role of the activating mutation Val617Phe of Janus kinase 2 gene in myeloproliferative diseases and significance of its detection].
Andrikovics H; Szilvási A; Meggyesi N; Király V; Halm G; Lueff S; Nahajevszky S; Mikala G; Sipos A; Lovas N; Csukly Z; Mátrai Z; Tamáska J; Tordai A; Masszi T
Orv Hetil; 2007 Feb; 148(5):203-10. PubMed ID: 17344140
[TBL] [Abstract][Full Text] [Related]
35. The rate of progression to polycythemia vera or essential thrombocythemia in patients with erythrocytosis or thrombocytosis.
Ruggeri M; Tosetto A; Frezzato M; Rodeghiero F
Ann Intern Med; 2003 Sep; 139(6):470-5. PubMed ID: 13679323
[TBL] [Abstract][Full Text] [Related]
36. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
Tefferi A
Am J Hematol; 2012 Mar; 87(3):285-93. PubMed ID: 22331582
[TBL] [Abstract][Full Text] [Related]
37. Difficulty distinguishing essential thrombocythaemia from polycythaemia vera in children with JAK2 V617F-positive myeloproliferative neoplasms.
Kucine N; Al-Kawaaz M; Hajje D; Bussel J; Orazi A
Br J Haematol; 2019 Apr; 185(1):136-139. PubMed ID: 29767848
[No Abstract] [Full Text] [Related]
38. Atypical haematological presentation in a case of polycythaemia vera with a new variant mutation detected in exon 12: c.1605G>T (p.Met535Ile).
Pita ASA; Azevedo APDS; Reichert A; Silva CJPD; Henriques V; Mendes DS; Reis AMB; Cerqueira R; Torres F; Viana JF
J Clin Pathol; 2018 Feb; 71(2):180-184. PubMed ID: 29021147
[TBL] [Abstract][Full Text] [Related]
39. Polycythemia vera: scientific advances and current practice.
Tefferi A; Spivak JL
Semin Hematol; 2005 Oct; 42(4):206-20. PubMed ID: 16210034
[TBL] [Abstract][Full Text] [Related]
40. [From gene to disease; JAK2 and polycythaemia vera].
Koene HR; Biemond BJ; van der Schoot CE
Ned Tijdschr Geneeskd; 2007 Aug; 151(32):1784-7. PubMed ID: 17822250
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
